Neuchâtel and Châtel-St-Denis, January 17, 2022
Centredoc acquires the patent analytics business from IPStudies
CENTREDOC and IPStudies today announced that CENTREDOC has acquired the patent analytics assets and operations from IPStudies as of Jan 1st, 2022. The transferred assets include the internationally renowned patent landscapes and patent monitoring services developed by IPStudies since 2014 on the revolutionary CRISPR genome editing technology. IPStudies customers will benefit from the latest advances in patent multi-categorization and multi-source feeds as developed by Centredoc with the breakthrough RAPID5 patent monitoring suite.
Corinne Le Buhan, CEO of IPStudies, said: “CENTREDOC has many years of experience in serving patent monitoring and business intelligence to a diversity of industries in Europe and will bring the IPStudies offering to the next level. With this transfer, we assure the sustainable growth of our patent analytics services demand, as biotech and medtech C-levels are more and more combining patent data with scientific publications and business intelligence to develop their IP strategy plans. ” Harald Jenny, CEO of CENTREDOC, said: “We are delighted to integrate the excellent patent analytics knowhow and life sciences expertise of IPStudies with a strong perspective of further growth through our latest RAPID5 tools and associated services.”
For more information:
Corinne LeBuhan, +41 79 787 57 46 Harald Jenny, +41 79 435 11 80
About CRISPR: https://www.ipstudies.ch/crispr-patent-analytics/
About RAPID5: https://www.centredoc.swiss/en/rapid/
Just as everyone, we heard the news on the first genetically engineered babies in mankind’s history. We took a closer look this morning into our patent data to check if there’s any published details already available. Indeed, the Chinese patent office publishes its data earlier than the other countries, sometimes as early as 3 months after the filing, so if the babies are born now, there’s a good chance that the Chinese patent data is already available.
Our expert Corinne Le Buhan will be speaking at the 10th anniversary of the Confederacy of European Patient Information User Groups (12 user groups, more than 1000 members) which will take place at Politecnico di Milano next week:
“On the relevance of deeper patent office register information for reporting to C-levels and investors – Biotech case studies“
We celebrate our 5th anniversary of biotech patent analytics in 2018 – that is a bit younger than the 25th anniversary of BIO2018, but we’re joining the party in Boston!
CRISPR and more generally gene editing is on many agendas this year, and we’re taking this opportunity to release a couple of new IPStudies analytics report out of our unique, exhaustive review of CRISPR-related worldwide patent applications since mid-2014:
- a zoom on the micro-organisms subset of the landscape;
- a review of the IP strategy of an unexpected player which has constantly ranked in the top applicants of our landscape, besides being more specialized in the ZFN technology: Sangamo Biosciences
The past six months have been very busy for IPStudies, serving our CRISPR monthly data monitoring to an increasing number of subscribers. We search, sort, analyze and classify an average of 100 new CRISPR patent families every month. We’ve also answered to a number of interviews with our latest statistical data as compiled in our August update of the 2017 CRISPR patent landscape. Here is a quick review of the past months significant updates in the CRISPR patent landscape:
The past 24 hours have brought new light and significant moves in the complex CRISPR patent landscape.
First (that was in European time zone!), our CRISPR expert Fabien Palazzoli celebrated the 1000th CRISPR patent family extraction out of the worldwide published patent databases. Our next monthly update will actually feature more than 1050 classified and categorized CRISPR patent families – more than 10 times the initial set of our first landscape release back in summer 2014!
The CRISPR patent landscape keeps on developing with in average a new patent publication every day. We have now searched, reviewed and categorized more than 920 patent families in our October 2016 CRISPR patent analytics data set.
The CRISPR patent landscape keeps on developing with in average a new patent publication every day. We have now searched, reviewed and categorized more than 850 patent families in our CRISPR patent analytics database.